Unicycive Therapeutics, Inc. (UNCY) - 10-K Summary
Business Context and Reporting Period
Company: Unicycive Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: Unicycive is a clinical-stage biotechnology company focused on kidney disease. Its pipeline consists of two primary candidates: Oxylanthanum Carbonate (OLC), a next-generation phosphate binder for hyperphosphatemia in dialysis patients, and UNI-494, a novel drug candidate for acute kidney injury (AKI). The company operates with a strategy of in-licensing assets and advancing them through regulatory approval.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Licensing Revenue | $0 | $675,000 |
| Research & Development Expenses | $20.0 million | $12.9 million |
| General & Administrative Expenses | $12.1 million | $8.5 million |
| Net Loss | $(36.7) million | $(30.5) million |
| Cash and Cash Equivalents (Year End) | $26.1 million | $9.7 million |
| Accumulated Deficit | $(101.3) million | $(64.5) million |
| Warrant Liability | $18.9 million | $13.1 million |
Note: The company has generated no product revenue to date. The 2023 licensing revenue was from an upfront payment related to a South Korea sublicense agreement.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by 20% to $36.7 million in 2024, driven by a 55% increase in R&D expenses ($7.1 million increase) and a 42% increase in G&A expenses ($3.6 million increase).
- Capital Raising: The company raised significant capital in 2024, including a $50 million private placement of Series B Convertible Preferred Stock in March and an At-The-Market (ATM) offering agreement with Guggenheim Securities in November. Cash balances increased from $9.7 million to $26.1 million.
- Regulatory Milestone: In September 2024, the company submitted a New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) via the 505(b)(2) pathway. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of June 28, 2025.
- Warrant Liability Fluctuation: The change in fair value of warrant liability resulted in a non-cash expense of $5.8 million in 2024, compared to $10.3 million in 2023.
Guidance, Outlook, and Risks
Outlook and Strategy:
- OLC Commercialization: Management is preparing a specialty commercial operation for the U.S. launch of OLC pending FDA approval. The company anticipates reimbursement via the Transitional Drug Add-on Payment Adjustment (TDAPA) under the Medicare ESRD Prospective Payment System, which begins including oral phosphate binders in January 2025.
- UNI-494 Status: Following FDA feedback recommending additional studies, the company has deprioritized further development of UNI-494 to focus resources on the commercialization of OLC.
- Liquidity: Management believes current resources are sufficient to fund operations for at least one year following the issuance of these financial statements.
- Going Concern: The company has incurred losses since inception and expects to continue doing so. Future profitability is uncertain and dependent on the successful approval and commercialization of OLC.
- Regulatory Approval: There is no guarantee that the FDA will approve OLC by the PDUFA date or at all. Failure to obtain approval would materially harm the business.
- Reimbursement Uncertainty: While the company expects TDAPA eligibility, there is no guarantee CMS will grant it. If denied, or if the bundled payment rate is insufficient, revenue potential could be significantly reduced.
- Nasdaq Compliance: The company received notice in July 2024 of non-compliance with the $1.00 minimum bid price requirement. It was granted an extension until July 7, 2025, to regain compliance. Failure to do so could result in delisting.
- Manufacturing: The company relies on third-party manufacturer Shilpa Medicare Ltd. The FDA conducted a surveillance inspection of Shilpa in March 2025, resulting in one procedural observation (Form 483).
Investor Verification Checklist
- FDA PDUFA Date: Verify the status of the OLC NDA review and confirm the June 28, 2025, decision date remains unchanged.
- TDAPA Application: Monitor for the submission and approval status of the Transitional Drug Add-on Payment Adjustment application with CMS, which is critical for reimbursement.
- Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the July 7, 2025, deadline to avoid delisting.
- Manufacturing Inspection: Review the outcome of the FDA Form 483 issued to Shilpa Medicare Ltd. in March 2025 to assess potential supply chain risks.
- Cash Burn Rate: Monitor quarterly cash flow statements to ensure the $26.1 million cash balance is sufficient to fund operations through the OLC launch and beyond, given the lack of product revenue.